Université Sorbonne Paris Cité (USPC) - Sciences Exactes et Technologie (SET) & Sciences de la Vie et de la Santé (SVS)
  • Upload

  • Se connecter

  • S'inscrire

Chercher sur MyScienceWork
News Publications Membres Événements

Recherche de publications

Sort by
  • Relevance
  • Published Date

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1...

Scherer, Joseph Nehmiz, Gerhard Steinmann, Gerhard G Böcher, Wulf O Sulkowski, Mark S Tarik Asselah Lalezari, Jacob Ferenci, Peter Fainboim, Hugo Leggett, Barbara ...

Published in Hepatology

Faldaprevir QD with PegIFN/RBV achieved consistently high SVR rates with acceptable tolerability and safety at all dose levels. The 120 and 240 mg QD doses are currently undergoing phase 3 evaluation. (HEPATOLOGY 2013;57:2143-2154).

A tamoxifen-inducible chimeric Cre recombinase specifically effective in the fetal and adult mouse liver.

Tannour-Louet, Mounia Porteu, Arlette Sophie Vaulont Kahn, Axel Vasseur-Cognet, Mireille

Published in Hepatology

The spatiotemporal control of somatic mutagenesis in mice is considered a promising step to determine the function of a given gene product in a defined population of cells at any given time during animal life and also to generate better mouse models of human diseases. To introduce defined mutations in a temporally controlled manner in the liver, we...

IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patien...

Bochud, Pierre-Yves Bibert, Stéphanie Kutalik, Zoltán Patin, Etienne Guergnon, Julien Nalpas, Bertrand Goossens, Nicolas Kuske, Lorenz Müllhaupt, Beat Gerlach, Tillman ...

Published in Hepatology

T-cell factor 4 and β-catenin chromatin occupancies pattern zonal liver metabolism in mice.

Gougelet, Angélique Torre, Cyril Veber, Philippe Sartor, Chiara Bachelot, Laura Denechaud, Pierre-Damien Godard, Cécile Moldes, Marthe Burnol, Anne-Françoise Dubuquoy, Céline ...

Published in The Journal of clinical endocrinology and metabolism

β-catenin patterns the zonal liver together with Tcf-4, Hnf-4α, and xenobiotic nuclear receptors. This network represses lipid metabolism and exacerbates glutamine, drug, and bile metabolism, mirroring HCCs with β-catenin mutational activation.

Iron- and inflammation-induced hepcidin gene expression in mice is not mediated by Kupffer cells in vivo.

Lou, Dan-Qing Lesbordes, Jeanne-Claire Nicolas, Gaël Viatte, Lydie Bennoun, Myriam Van Rooijen, Nico Kahn, Axel Renia, Laurent Sophie Vaulont

Published in Hepatology

Hepcidin, a recently discovered iron regulatory peptide, is believed to inhibit the release of iron from absorptive enterocytes and macrophages. Liver hepcidin synthesis is induced in vivo by iron stores and inflammation. The molecular basis of the regulation of hepcidin gene expression by these effectors in hepatocytes is currently unknown, althou...

HNF1B deficiency causes ciliary defects in human cholangiocytes.

Roelandt, Philip Antoniou, Aline Libbrecht, Louis Van Steenbergen, Werner Laleman, Wim Verslype, Chris Van der Merwe, Schalk Nevens, Frederik De Vos, Rita Fischer, Evelyne ...

Published in Hepatology

Heterozygous deletion or mutation in hepatocyte nuclear factor 1 homeobox B/transcription factor 2 (HNF1B/TCF2) causes renal cyst and diabetes syndrome (OMIM #137920). Mice with homozygous liver-specific deletion of Hnf1β revealed that a complete lack of this factor leads to ductopenia and bile duct dysplasia, in addition to mild hepatocyte defects...

Protease profiling of liver fibrosis reveals the ADAM metallopeptidase with thrombospondin type 1 motif, 1 as a central ...

Bourd-Boittin, Katia Bonnier, Dominique Leyme, Anthony Mari, Bernard Pierre Tuffery Michel Samson Ezan, Frédéric Georges Baffet Theret, Nathalie

Published in Hepatology

During chronic liver disease, tissue remodeling leads to dramatic changes and accumulation of matrix components. Matrix metalloproteases and their inhibitors have been involved in the regulation of matrix degradation. However, the role of other proteases remains incompletely defined. We undertook a gene‐expression screen of human liver fibrosis sam...

Upregulation of the tumor suppressor gene menin in hepatocellular carcinomas and its significance in fibrogenesis.

Zindy, Pierre J L'Helgoualc'h, Annie Bonnier, Dominique Le Béchec, Antony Bourd-Boitin, Katia Zhang, Chang Xian Musso, Orlando Glaise, Denise Troadec, Marie Bérangère Loréal, Olivier ...

Published in Hepatology

The molecular mechanisms underlying the progression of cirrhosis toward hepatocellular carcinoma were investigated by a combination of DNA microarray analysis and literature data mining. By using a microarray screening of suppression subtractive hybridization cDNA libraries, we first analyzed genes differentially expressed in tumor and nontumor liv...

TRAIL but not FasL and TNFα, regulates IL-33 expression in murine hepatocytes during acute hepatitis.

Arshad, Muhammad Imran Piquet-Pellorce, Claire L'Helgoualc'h, Annie Rauch, Michel Patrat-Delon, Solène Ezan, Frédéric Lucas-Clerc, Catherine Nabti, Sabrina Agnès Lehuen Cubero, Francisco Javier ...

Published in Hepatology

Interleukin (IL)-33, a member of the IL-1 cytokine family, positively correlates with acute hepatitis and chronic liver failure in mice and humans. IL-33 is expressed in hepatocytes and is regulated by natural killer T (NKT) cells during concanavalin A (ConA)-induced acute liver injury. Here, we investigated the molecular mechanisms underlying the ...

TRAIL but not FasL and TNFα, regulates IL-33 expression in murine hepatocytes during acute hepatitis.

Arshad, Muhammad Imran Piquet-Pellorce, Claire L'Helgoualc'h, Annie Rauch, Michel Patrat-Delon, Solène Ezan, Frédéric Lucas-Clerc, Catherine Nabti, Sabrina Lehuen, Agnès Cubero, Francisco Javier ...

Published in The Journal of clinical endocrinology and metabolism

The expression of IL-33 during acute hepatitis is dependent on TRAIL, but not on FasL or TNFα.

  • ← Previous
  • 1 (current)
  • 2
  • 3
  • 4
  • Next →
Powered by Polaris
  • A propos de l'USPC
  • FAQ